Saturday 17 October 2026
Export STIM’s income statement to Excel — free account
Neuronetics, Inc.
STIM Healthcare Medical Devices
Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.08%, EPS grew 66.7%, free cash flow grew 62.1% and total debt rose 10.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
1.89
0.06
−3.08%
Follow STIM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.41 | 0.61 | 0.67 | 0.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(234.08) | 100.23 | (10.71) | (94.31) | |
P/B ratio |
5.86 | 3.47 | 5.91 | 4.39 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.76 | 0.91 | 1.03 | 0.94 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.64) | (6.68) | (12.23) | (14.07) | |
EV/FCF |
(7.48) | (6.43) | (11.55) | (12.92) | |
Quick Ratio |
1.86 | 1.68 | 1.25 | 1.46 | |
Current Ratio |
2.24 | 2.02 | 1.67 | 1.88 | |
Net Debt/EBITDA |
(4.82) | (7.35) | (5.10) | (47.07) | |
Debt/Assets |
45.15% | 46.49% | 48.87% | 46.77% | |
Debt/Equity |
2.09 | 2.51 | 3.59 | 2.84 | |
Asset Turnover |
1.18 | 1.06 | 1.13 | 1.17 | |
Operating CF/Net income |
0.09 | (0.13) | 0.87 | 0.29 | |
Capex/Depreciation |
(0.13) | (0.28) | (0.23) | (0.57) | |
Interest Coverage |
(3.32) | (2.18) | (3.97) | (0.71) | |
Research and Development Expense of Revenue |
4.03% | 3.99% | 3.96% | 3.21% | |
Selling, General and Administrative Expense of Revenue |
61.47% | 60.04% | 69.03% | 51.45% | |
Intangible Assets out of Total Assets |
0.28 | 0.30 | 0.33 | 0.31 | |
Share Based Compensation of Revenue |
3.78% | 5.22% | 4.87% | 1.66% | |
Graham Net Nets |
(0.27) | (0.59) | (0.61) | (0.60) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(30.04%) | (42.75%) | (37.24%) | (33.85%) | |
Free Cash Flow Yield |
(16.63%) | (23.27%) | (13.43%) | (11.81%) | |
Revenue per Share |
0.55 | 0.63 | 0.50 | 0.57 | |
Operating CF per Share |
(0.01) | 0.01 | (0.14) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.01) | 0.01 | (0.14) | (0.02) | |
Cash per Share |
0.51 | 0.52 | 0.28 | 0.34 | |
Shareholders Equity per Share |
0.47 | 0.40 | 0.25 | 0.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.47 | 0.40 | 0.25 | 0.30 | |
Free Cash Flow |
(0.90) | 0.69 | (9.59) | (1.42) | |
Working Capital |
35.95 | 31.03 | 18.89 | 24.92 | |
Capital Expenditures |
(0.11) | (0.22) | (0.17) | (0.42) | |
Net Current Asset Value |
(49.22) | (53.76) | (61.20) | (56.66) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
19.24 | 20.59 | 21.55 | 21.46 | |
Average Payables |
7.43 | 10.91 | 9.96 | 11.07 | |
Average Inventory |
4.64 | 4.29 | 4.39 | 5.22 | |
Average Assets |
109.79 | 141.23 | 133.71 | 133.09 | |
Average Common Equity |
20.37 | 29.02 | 28.30 | 26.57 |
Columns are period end dates